| Therapeutic | Eculizumab |
| Target | C5 |
| Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK |
| 100% seqID Fv Structure | 5i5k [Fvs: HL, XY] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5i5k [Fvs: HL, XY] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (June '19) | Approved |
| Estimated Status (June '19) | Active |
| Recorded Developmental Technology | GS Gene Expression System |
| INN Year Proposed | 2002 |
| INN Year Recommended | 2003 |
| Companies Involved | Alexion Pharmaceuticals, Brigham and Womens Hospital, Chiba University, Handok Inc |
| Conditions Approved | Haemolytic uraemic syndrome, Myasthenia gravis, Paroxysmal nocturnal haemoglobinuria |
| Conditions Active | Neuromyelitis optica, Delayed graft function, Guillain-Barre syndrome, Renal transplant rejection |
| Conditions Discontinued | Antiphospholipid syndrome, Heart transplant rejection, Adult respiratory distress syndrome, Age-related macular degeneration, Allergic asthma, Autoimmune haemolytic anaemia, Bullous pemphigoid, Dermatomyositis, Glomerulonephritis, Idiopathic thrombocytopenic purpura, Lupus nephritis, Membranous glomerulonephritis, Motor neuron disease, Psoriasis, Rheumatoid arthritis, Systemic lupus erythematosus |
| Notes |
